[Prognostic indicators in stage I non-small cell lung cancer].
BACKGROUND
Determinating the prognosis of patients with stage I non-small cell lung cancer (NSCLC) is a challenge. Since up to 30% of patients who have undergone surgical resection experience recurrence, generally in distant organs, it is reasonable to postulate that neo-adjuvant or adjuvant treatments might be useful. Better knowledge of prognostic factors could perhaps define which patient populations should be targeted with such treatments.


BACKGROUND
Numerous potential prognostic factors, relating to the disease (TNM classification, histology, tumor size, blood vessels invasion, micro-metastasis, serum or molecular markers), the patient (gender, age, co-morbidity) as well as the treatment (delay, resection, lymph node dissection, neo-adjuvant and adjuvant treatments), are discussed.


CONCLUSIONS
These prognostic factors should be integrated into the design of future clinical trials of chemotherapy and/or radiotherapy attempting to evaluate the effectiveness of various combinations of neo-adjuvant or adjuvant therapies.


CONCLUSIONS
These factors may offer the opportunity to clinically and biologically characterize the different subgroups of patients, leading to a more rational, and perhaps individualized, choice of therapy.
Barlési
F
F
Département des Maladies Respiratoires, Université de la Méditerrannée, Hôpitaux de Marseille, France. Fabrice.Barlesi@mail.ap-hm.fr
Doddoli
C
C
Greillier
L
L
Astoul
P
P
Giudicelli
R
R
Fuentes
P
P
Thomas
P
P
D014408:Biomarkers, Tumor / Q000097:blood; D002289:Carcinoma, Non-Small-Cell Lung / Q000097:blood / Q000150:complications / Q000401:mortality* / Q000473:pathology / Q000556:secondary / Q000628:therapy; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000097:blood / Q000150:complications / Q000401:mortality* / Q000473:pathology / Q000628:therapy; D008297:Male; D009367:Neoplasm Staging; D011379:Prognosis; D015996:Survival Rate
D014408:Biomarkers, Tumor